Editorial| Volume 45, ISSUE 3, P316-317, February 2009

Adjuvant 5-FU based chemotherapy for colon cancer: Match or miss the mismatch?

Published:December 19, 2008DOI:
      Mismatch repair recognises base–base mismatches and insertion/deletion loops and thus it is essential for maintaining the fidelity of DNA replication.
      • Jiricny J.
      The multifaceted mismatch-repair system.
      The deficiency of DNA mismatch repair due to mutations of the proteins involved in this mechanism predisposes to cancer and is responsible for mutator phenotype. Laboratory studies have indicated that mismatch repair deficiency confers resistance to several anticancer drugs, including cisplatin, methylating agents and some antimetabolites. A significant proportion of intestinal cancers, approximately 10–15%, are mismatch repair deficient and thus it is certainly pertinent to ask the question whether the anticancer therapies have a different efficacy depending on mismatch repair status.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jiricny J.
        The multifaceted mismatch-repair system.
        Nat Rev Mol Cell Biol. 2006; 7: 335-346
        • Jover R.
        • Zapater P.
        • Castells A.
        • et al.
        The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
        Eur J Cancer. 2009; 45: 365-373
        • Hegi M.E.
        • Diserens A.C.
        • Gorlia T.
        • et al.
        MGMT gene silencing and benefit from temozolomide in glioblastoma.
        N Engl J Med. 2005; 352: 997-1003
        • Catapano C.V.
        • Broggini M.
        • Erba E.
        • et al.
        In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
        Cancer Res. 1987; 47: 4884-4889
        • Damia G.
        • D’Incalci M.
        Targeting DNA repair as a promising approach in cancer therapy.
        Eur J Cancer. 2007; 43: 1791-1801